Scilex Announces Collaboration To Leverage ACEA Therapeutics' R&D Expertise To Support The Expansion Of ZTlido Program In Ex-U.S. And Potentially Provide Additional Access To Patients In Certain Key Markets In Far East Region
Portfolio Pulse from Benzinga Newsdesk
Scilex Holding Company (NASDAQ:SCLX) has announced a collaboration with ACEA Therapeutics to expand the ZTlido program in Greater China. ACEA will serve as the exclusive distributor in the region and will explore potential commercialization of ZTlido and other non-opioid pain products from Scilex.
July 17, 2024 | 1:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scilex Holding Company has entered into a collaboration with ACEA Therapeutics to expand the ZTlido program in Greater China. This partnership could enhance Scilex's market reach and revenue potential in the region.
The collaboration with ACEA Therapeutics provides Scilex with exclusive distribution rights in Greater China, which could significantly increase market access and revenue for ZTlido and other non-opioid pain products. The potential minimum purchase commitment from ACEA further strengthens the financial outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100